[February 22, 2018]

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 - Key Companies Include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer - ResearchAndMarkets.com

The "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" report has been added to ResearchAndMarkets.com's offering.

"Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions.

Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

Ureter or reteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of the disease include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. There are a total of nine products in development for this indication, by six companies and two academic institutions.

These products act on a wide range of targets, including a number of growth factor receptors and intracellular signal transducers. Within bladder cancer, the most commonly developed targets are Programmed Cell Death 1 Ligand 1 and Tubulin.

Scope

• Which companies are the most active within each pipeline?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Table Of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved In Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4hs9xs/bladder_and?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180222006439/en/

[ Back To TMCnet.com's Homepage ]